A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-581 in Healthy Subjects
Latest Information Update: 31 Dec 2025
At a glance
- Drugs VX 581 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Vertex Pharmaceuticals
Most Recent Events
- 29 Dec 2025 Status changed from not yet recruiting to recruiting.
- 24 Dec 2025 New trial record